• Journal of Investigative Oncology
Research Article

Cytoreductive Surgery and HIPEC for the Prevention and Treatment of Colorectal Peritoneal Metastases: Lessons Learnt from Three Recent Randomized Trials

Journal of Investigative Oncology [2020; 1(1):11-15]
Received: 29 March 2020, Accepted: 05 April 2020, Published: 10 April 2020

The final results of three large randomized trials that have recently addressed the role of Hyper thermic Intraperitoneal Chemotherapy (HIPEC) in the management of colorectal cancer peritoneal metastases (CRC-PM) are presented and critically appraised. Prodige-7 trial randomized patients with established CRC-PM after optimal cytoreductive surgery (residual tumor <1mm) to no HIPEC vs. oxaliplatin-based HIPEC. COLOPEC randomly assigned patients who had curative-intent surgery for pT4a/b or perforated CRC to oxaliplatin-based HIPEC given either at primary resection, or staged 5-8 weeks later, and followed by adjuvant systemic chemotherapy (s-CT), vs. standard adjuvant s-CT only. ProphyloCHIP trial randomized HIPEC combined with second-look surgery after adjuvant s-CT vs. standard surveillance in high-risk patients, defined as history of peritoneal or ovarian metastases or perforated primary CRC.

Recommended Articles

Our articles most useful